25 years of studies on the efficacy and safety of different formulations of naltrexone for the opioid use disorder treatment
https://doi.org/10.31363/2313-7053-2025-4-2-1136
Abstract
The article overviews the results of the studies of different formulations of opioid antagonist naltrexone (oral, injectable and implantable) for stabilization of remission and relapse prevention in patients with opioid dependence conducted by authors during the last twenty five years. Based on the results of these studies, long-acting sustained release formulations of naltrexone (injectable and implantable) are more effective than oral formulation and may solve the problem of poor adherence to oral naltrexone. Naltrexone implant is more effective that oral formulation for both relapse prevention and improving adherence to antiretroviral therapy in patients with opioid dependence. Depot formulations of naltrexone are effective, well tolerated and open a new perspective for the treatment of opioid dependence.
About the Authors
E. M. Krupitsky
V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology; I.P. Pavlov First St. Petersburg State Medical University
Russian Federation
Russian Federation
Evgeny M. Krupitsky
Saint Petersburg
E. A. Blokhina
I.P. Pavlov First St. Petersburg State Medical University
Russian Federation
Russian Federation
Elena A. Blokhina
Saint Petersburg
T. S. Yaroslavtseva
I.P. Pavlov First St. Petersburg State Medical University
Russian Federation
Russian Federation
Tatiana S. Yaroslavtseva
Saint Petersburg
E. E. Zvartau
I.P. Pavlov First St. Petersburg State Medical University
Russian Federation
Russian Federation
Edwin E. Zvartau
Saint Petersburg
References
1. Anohina IP. Main biological mechanisms of psychoactive substance addiction. Voprosy narkologii. 2013;6:40-59. (In Russ.).
2. Krupitsky EM, Blokhina EA. Use of prolonged-release forms of naltrexon for the treatment of opiate dependence. Voprosy narkologii. 2010;4:32-43. (In Russ.).
3. Carroll KM, Ball SA, Nich C, O'Connor PG, Eagan DA, Frankforter TL, Triffleman EG, Shi J, Rounsaville BJ. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry. 2001;58(8):755-61. https://doi.org/10.1001/archpsyc.58.8.755
4. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63(2):210-8. https://doi.org/10.1001/archpsyc.63.2.210
5. Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res. 2006 Mar;30(3):480-90. https://doi.org/10.1111/j.1530-0277.2006.00052.x
6. Fishman M. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone. Addiction. 2008 Aug;103(8):1399-401. https://doi.org/10.1111/j.1360-0443.2008.02252.x
7. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva: World Health Organization; 2009.
8. Hulse GK, Morris N, Arnold-Reed D, Tait RJ. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry. 2009;66(10):1108-15. https://doi.org/10.1001/archgenpsychiatry.2009.130
9. Kleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci. 2007;9(4):455-70. https://doi.org/10.31887/DCNS.2007.9.2/hkleber
10. Krupitsky E. Injectable extended-release naltrexone for the prevention of relapse to opioid dependence following opioid detoxification. Neuropsychiatry.2012;2(4):355-62.
11. Krupitsky EM, Blokhina EA. Long-acting depot formulations of naltrexone for heroin dependence: a review. Curr Opin Psychiatry. 2010;23(3):210-4. https://doi.org/10.1097/YCO.0b013e3283386578
12. Krupitsky E, Blokhina E, Zvartau E, Verbitskaya E, Lioznov D, Yaroslavtseva T, et al. Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial. Lancet HIV. 2019;6(4):e221-e229. https://doi.org/10.1016/S2352-3018(18)30362-X
13. Krupitsky EM, Burakov AM, Didenko TY, Romanova T, Grinenko NI, Slavina TY, Grinenko AY, Tcheremissine O. Effects of citalopram treatment of protracted withdrawal (syndrome of anhedonia) in patients with heroin addiction. Addictive Disorders and Their Treatment. 2002;1(1):29-33. https://doi.org/10.1097/00132576-200205000-00006
14. Kruptisky EM, Burakov AM, Tsoy MV, Egorova VY, Slavina TY, Grinenko AY, Zvartau EE, Woody GE. Overcoming opioid blockade from depot naltrexone (Prodetoxon). Addiction. 2007;102(7):1164-5. https://doi.org/10.1111/j.1360-0443.2007.01817.x
15. Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Tsoy M, Wahlgren V, et al. Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia. Drug Alcohol Depend. 2013;132(3):674-80. https://doi.org/10.1016/j.drugalcdep.2013.04.021
16. Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M, et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry. 2012;69(9):973-81. https://doi.org/10.1001/archgenpsychiatry.2012.1a
17. Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M, et al. Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant. Am J Drug Alcohol Abuse. 2016;42(5):614-20. https://doi.org/10.1080/00952990.2016.1197231
18. Krupitsky EM, Zvartau EE, Masalov DV, Tsoi MV, Burakov AM, Egorova VY, et al. Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat. 2004;26(4):285-94. https://doi.org/10.1016/j.jsat.2004.02.002
19. Krupitsky EM, Zvartau EE, Masalov DV, Tsoy MV, Burakov AM, Egorova VY, et al. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat. 2006;31(4):319-28. https://doi.org/10.1016/j.jsat.2006.05.005
20. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506-13. https://doi.org/10.1016/S0140-6736(11)60358-9
21. Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013;108(9):1628-37. https://doi.org/10.1111/add.12208
22. Kunøe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M, Kristensen Ø, Waal H. Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. Br J Psychiatry. 2009;194(6):541-6. https://doi.org/10.1192/bjp.bp.108.055319
23. Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309-18. https://doi.org/10.1016/S0140-6736(17)32812-X
24. Nunes EV, Rothenberg JL, Sullivan MA, Carpenter KM, Kleber HD. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drug Alcohol Abuse. 2006;32(4):503-17. https://doi.org/10.1080/00952990600918973
25. O'Brien C, Cornish JW. Naltrexone for probationers and parolees. J Subst Abuse Treat. 2006;31(2):107-11. https://doi.org/10.1016/j.jsat.2006.06.002
26. Opheim A, Benth JŠ, Solli KK, Kloster PS, Fadnes LT, Kunøe N, Gaulen Z, Tanum L. Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial. Contemp Clin Trials. 2023;135:107360. https://doi.org/10.1016/j.cct.2023.107360
27. Opheim A, Gaulen Z, Solli KK, Latif ZE, Fadnes LT, Benth JŠ, Kunøe N, Tanum L. Risk of Relapse Among Opioid-Dependent Patients Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone: A Randomized Clinical Trial. Am J Addict. 2021;30(5):453-60. https://doi.org/10.1111/ajad.13151
28. Preston KL, Silverman K, Umbricht A, DeJesus A, Montoya ID, Schuster CR. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend. 1999;54(2):127-35. https://doi.org/10.1016/s0376-8716(98)00152-5
29. Roth A, Hogan I, Farren C. Naltrexone plus group therapy for the treatment of opiate-abusing health-care professionals. J Subst Abuse Treat. 1997;14(1):19-22. https://doi.org/10.1016/s0740-5472(96)00164-x
30. Rothenberg JL, Sullivan MA, Church SH, Seracini A, Collins E, Kleber HD, Nunes EV. Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J Subst Abuse Treat. 2002;23(4):351-60. https://doi.org/10.1016/s0740-5472(02)00301-x
31. Sinha R, Kimmerling A, Doebrick C, Kosten TR. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings. Psychopharmacology (Berl). 2007;190(4):569-74. https://doi.org/10.1007/s00213-006-0640-8
32. Tanum L, Solli KK, Latif ZE, Benth JŠ, Opheim A, Sharma-Haase K, Krajci P, Kunøe N. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial. JAMA Psychiatry. 2017;74(12):1197-205. https://doi.org/10.1001/jamapsychiatry.2017.3206
33. Volpicelli RG, Fenton M. Sustained-release naltrexone formulations for the treatment of alcohol and opioid dependence. Future Neurology. 2006;1(4):389-98. https://doi.org/10.2217/14796708.1.4.389
34. Washton AM, Pottash AC, Gold MS. Naltrexone in addicted business executives and physicians. J Clin Psychiatry. 1984;45(9 Pt 2):39-41
Review
For citations:
Krupitsky E.M., Blokhina E.A., Yaroslavtseva T.S., Zvartau E.E. 25 years of studies on the efficacy and safety of different formulations of naltrexone for the opioid use disorder treatment. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. (In Russ.) https://doi.org/10.31363/2313-7053-2025-4-2-1136
Views:
19
Email this article 